Plate R, Plaum M J, de Boer T, Andrews J S, Rae D R, Gibson S
Department of Medicinal Chemistry, Scientific Development Group N.V. Organon, The Netherlands.
Bioorg Med Chem. 1996 Feb;4(2):227-37. doi: 10.1016/0968-0896(96)00001-6.
A series of 3-(pyrazolyl)-1,2,5,6-tetrahydropyridine derivatives (B) was synthesized and tested for muscarinic activity in receptor binding assays using [3H]-oxotremorine-M (3H-OXO-M) and [3H]-pirenzepine (3H-PZ) as ligands. Potential muscarinic agonistic or antagonistic properties of the compounds were determined using binding studies measuring their potencies to inhibit the binding of 3H-OXO-M and 3H-PZ. Preferential inhibition of 3H-OXO-M binding was used as an indicator for potential muscarinic agonistic properties; this potential was confirmed in functional studies on isolated organs. All compounds with agonistic properties showed 3H-PZ/3H-OXO-M potency ratios in excess of 20. In contrast, for antagonists this ratio was found to be close to unity. Mono-halogenation resulted in compounds (4b and 4d) with M3 agonistic properties as shown by their atropine sensitive stimulant properties in the guinea pig ileum, but with very little or no M1 activity. Some minor in vivo effects were observed for both these compounds, with the iodinated compound 4d inducing salivation. Compound 4d also showed some positive mnemonic properties in rats where spatial short-term memory had been compromised by temporary cholinergic depletion. These data indicate that some M3 agonism may be desired in therapeutic agents aimed at the treatment of the cognitive deficits of Alzheimer's disease patients.
合成了一系列3-(吡唑基)-1,2,5,6-四氢吡啶衍生物(B),并使用[3H]-氧代震颤素-M(3H-OXO-M)和[3H]-哌仑西平(3H-PZ)作为配体,在受体结合试验中测试其毒蕈碱活性。通过测量化合物抑制3H-OXO-M和3H-PZ结合的效力的结合研究,确定了这些化合物潜在的毒蕈碱激动或拮抗特性。优先抑制3H-OXO-M结合被用作潜在毒蕈碱激动特性的指标;这一潜力在离体器官的功能研究中得到了证实。所有具有激动特性的化合物的3H-PZ/3H-OXO-M效力比均超过20。相比之下,对于拮抗剂,该比值接近1。单卤代产生了具有M3激动特性的化合物(4b和4d),如它们在豚鼠回肠中对阿托品敏感的刺激特性所示,但几乎没有或没有M1活性。观察到这两种化合物都有一些轻微的体内效应,碘化化合物4d可诱导流涎。化合物4d在大鼠中也显示出一些积极的记忆特性,在这些大鼠中,空间短期记忆因暂时的胆碱能耗竭而受损。这些数据表明,在旨在治疗阿尔茨海默病患者认知缺陷的治疗药物中,可能需要一些M3激动作用。